1 / 6

PhD Student : NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169

« MONITORING OF AZATHIOPRINE THERAPY IN PEDIATRIC POPULATION: RELATION PHARMACOKINETIC/PHARMACODYNAMIC IN AUTOIMMUNE DISEASES  ». PhD Student : NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169 Department of Clinical Pharmacy Pharmacokinetics and Drug Evaluation Laboratory

darius-pitts
Download Presentation

PhD Student : NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. « MONITORING OF AZATHIOPRINE THERAPY IN PEDIATRIC POPULATION: RELATION PHARMACOKINETIC/PHARMACODYNAMIC IN AUTOIMMUNE DISEASES » PhD Student: NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169 Department of Clinical Pharmacy Pharmacokinetics and Drug Evaluation Laboratory Lyon 1 University 11.2010 – 11.2013

  2. INTRODUCTION - OBJECTIVES • Autoimmune diseases:arise from an overactive immune response of the body against its cell. • Inflammatory bowel disease (IBD):a group of disorders in which the intestines become inflamed • Autoimmune hepatitis (AIH): the immune systems attacks liver cells • Dermatology diseases: Skin diseases • Azathioprine (AZA):-an immunosuppressive drug, complex metabolism 6-TGN: an active metabolite, 250-450 pmol/8.108 RBCs: therapeutic range Limited data: on AZA dose for children Suggest AZA dose for children OBJECTIVES Evaluate efficacy, toxicity in function of AZA dose and 6TGN level

  3. AZA METABOLISM AZA 6MP TPMT XOD 6-MeMP 6-TUA 6-TGMP Mono P Inactive metabolite, TOXICITY 6-TGDP Di P 6-TGN Active metabolite Most active 6-TGTP Tri P

  4. 1st year AZA DOSE FOR IBD CHILDREN • Method: 64 patients less than 19 years • received AZA mono-therapy for at least 3 months • - 3 dose groups: below 2, 2-2.5 (standard dose), greater than 2.5 mg/kg/d - Remission: PCDAI <10 - Toxicity: Leukopenia; Lymphopenia; Hepatotoxicity, Pancreatotoxicity - Metabolite assay (6-TGN, Me6-MPN): HPLC • Objective: - Suggest AZA dose for pediatric IBD patients - Investigate efficacy, toxicity in function of AZA dose and 6-TGN level • AZA dose below 2 mg/kg/d appears effective in pediatric patients (94%) • Children may achieve remission when 6-TGN level below 250 nmol/h/mL RBCs (85%) • Therapeutic range 250-450 pmol/8.108 RBCs seems not appropriate RESULTS Further Studies

  5. INFLUENCE OF AGE ON UTILITY OF AZA DOSE IN IBD CHILDREN Now • Our 1st study: suggest dose for IBD children less than 19 years AZA dose less than 2 mg/kg/d is effective • 1published study: suggest dose greater than 3 mg/kg/d for children 6 years old or younger Investigate influence of age on AZA efficacy and toxicity in function of AZA dose and 6-TGN level • Divide studied population into 2 age groups: the adolescent • ( more than 11 years), the young children (11 years and younger) Method: • Data of each groups is subdivided into groups of AZA dose: • Below 2 mg/kg/d, 2-2.5 mg/kg/d, more than 2.5 mg/kg/d

  6. STUDY ON AZA THERAPY IN CHILDREN WITH SOME OTHER AUTOIMMUNE DISEASES Next years • Autoimmune Hepatitis (AIH) and Dermatology diseases Collect pediatric patients treated with AZA Evaluate efficacy, toxicity - Investigate therapeutic range of 6-TGN level - Optimize AZA dose for children with these diseases • 6TGN:-correspond to the mono, di, tri-phosphate forms of 6-Thioguanosine • (Tri phosphate form was considered to be the major active compound) • Previous studies determined • total 6-TGN levels Contradictory data on relation between 6-TGN level and efficacy • Develop a method to determine levels of these 6-TGN forms in children • Investigate the relation between each form of 6-TGN and efficacy in children

More Related